| Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates (NCT00130936) | AHS Cancer Control Alberta | 2005-10-01 |
| NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) (NCT00248404) | Kiadis Pharma | 2005-09-01 |
| Study Evaluating TTI-237 in Advanced Malignant Solid Tumors. (NCT00195325) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-08-01 |
| Study of Dasatinib in Patients With Advanced Solid Tumors (NCT00162214) | Bristol-Myers Squibb | 2005-08-01 |
| Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic (NCT00127829) | AstraZeneca | 2005-07-01 |
| A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) (NCT00127127) | Merck Sharp & Dohme LLC | 2005-06-10 |
| Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies (NCT00129337) | Peregrine Pharmaceuticals | 2005-06-01 |
| Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary (NCT00201734) | Ohio State University Comprehensive Cancer Center | 2005-06-01 |
| Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors (NCT00105170) | Biogen | 2005-01-01 |
| Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas (NCT00389077) | AEterna Zentaris | 2005-01-01 |
| Rare Tumor Case Review (NCT00229879) | Children's Healthcare of Atlanta | 2004-12-01 |
| Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors (NCT00187174) | St. Jude Children's Research Hospital | 2004-10-01 |
| A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies (NCT00207025) | Bristol-Myers Squibb | 2004-10-01 |
| Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy (NCT00222443) | University of Oklahoma | 2004-09-01 |
| MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors (NCT00207103) | Bristol-Myers Squibb | 2004-09-01 |
| Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors (NCT00091806) | Amgen | 2004-08-01 |
| Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NCT00323934) | Mirati Therapeutics Inc. | 2004-04-01 |
| Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy (NCT00230217) | Sanofi | 2004-03-01 |
| Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors (NCT00093873) | Amgen | 2003-07-01 |
| An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours (NCT02182206) | Boehringer Ingelheim | 2003-06-01 |
| Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) (NCT00060645) | Merck Sharp & Dohme LLC | 2003-05-01 |
| Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) (NCT00060632) | Merck Sharp & Dohme LLC | 2003-04-01 |
| Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer (NCT00171587) | Novartis | 2002-05-01 |
| Expression of NIS Protein and mRNA in Thyroid Tumors (NCT00459498) | University of Sao Paulo | 2002-04-01 |
| Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer (NCT00024492) | INSYS Therapeutics Inc | 2001-08-01 |
| Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction (NCT00113113) | Astex Pharmaceuticals, Inc. | 2001-08-01 |
| Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors (NCT00201812) | Ohio State University Comprehensive Cancer Center | 2000-11-01 |
| Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) (NCT00179764) | Ann & Robert H Lurie Children's Hospital of Chicago | 2000-03-10 |
| Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors (NCT00149006) | Hadassah Medical Organization | 1996-12-01 |
| Ultrasonic Evaluation of Ocular Tissues (NCT00279695) | Weill Medical College of Cornell University | 1996-01-01 |
| Comparing Magnetic Resonance Imaging/Spectroscopy Techniques (NCT00001219) | National Institutes of Health Clinical Center (CC) | 1987-06-18 |
| GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers (NCT01437280) | Baylor College of Medicine | |
| Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade (NCT00129207) | Millennium Pharmaceuticals, Inc. | |
| Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors (NCT00102830) | Amgen | |
| Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma. (NCT00298779) | Millennium Pharmaceuticals, Inc. | |